Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Study Phase
Phase 3
Study Completion Date
January 2011
NCT00626548Uploaded 08-04-2014
Available for Download
PDS UID: Prostat_AstraZe_2008_103
A Phase III, Randomised, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of Once-daily Orally Administered ZD4054 (Zibotentan) 10 mg in Non-metastatic Hormone-resistant Prostate Cancer Patients
PDS UID: Prostat_Multipl_2008_406Go to Study
Enhancing the Analytic Capacity of Prostat_AstraZe_2008_103 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey
PROTOCOLZibotentan CSP D4320C00015 With Redactions_Redacted.pdf
CRFNot Provided
DATA DICTIONARYRDB Standards - D4320C00015 and D4320C00033.xlsx
DATA (COMPARATOR ARM)D4320C00015 De-Identified RDB